Cáncer de endometrio: influencia del tratamiento en la calidad de vida y función sexual

Objective: To determine the influence of the treatment received, in the quality of life and sexual function of women survivors of endometrial cancer during the period: January 2017 - August 2019. Methods: Prospective, observational, analytical, longitudinal research, in endometrial cancer survivors, to whom the SF-12 health questionnaire and the Female Sexual Function Index were applied, to determine the quality of life and sexual health respectively, before and after treatment. Results: Patients exposed to surgery alone who perceived deterioration in their physical health after treatment was 56.5 %, while in those exposed to surgery plus adjuvant treatment was 97.4 %, in those exposed to neoadjuvant treatment plus surgery was 100.0 % as in those exposed to external radiotherapy only. No patient treated with surgery or external radiotherapy alone perceived deterioration in their mental health after treatment, while the patients undergoing surgery plus adjuvant treatment the percentage was 33.33 % and in those exposed to neoadjuvant treatment plus surgery was 12.50 %. 40 women had sexual dysfunction after treatment, 65.5 % of women undergoing surgery alone, 93.3 % of those undergoing surgery plus adjuvant treatment and 100 % of those exposed to neoadjuvant treatment plus surgery. Conclusion: The prevalence of deterioration of physical health, mental health and sexual dysfunction in women exposed to combined treatments was higher than in those exposed to surgery alone. Key words: Endometrial Cancer, Quality of Life, Sexual Function, Physical Health, Mental Health.

Molecular Response to Combined Molecular- and External Radiotherapy in Head and Neck Squamous Cell Carcinoma (HNSCC)

Combination treatment of molecular targeted and external radiotherapy is a promising strategy and was shown to improve local tumor control in a HNSCC xenograft model. To enhance the therapeutic value of this approach, this study investigated the underlying molecular response. Subcutaneous HNSCC FaDuDD xenografts were treated with single or combination therapy (X-ray: 0, 2, 4 Gy; anti-EGFR antibody (Cetuximab) (un-)labeled with Yttrium-90 (90Y)). Tumors were excised 24 h post respective treatment. Residual DNA double strand breaks (DSB), mRNA expression of DNA damage response related genes, immunoblotting, tumor histology, and immunohistological staining were analyzed. An increase in number and complexity of residual DNA DSB was observed in FaDuDD tumors exposed to the combination treatment of external irradiation and 90Y-Cetuximab relative to controls. The increase was observed in a low oxygenated area, suggesting the expansion of DNA DSB damages. Upregulation of genes encoding p21cip1/waf1 (CDKN1A) and GADD45α (GADD45A) was determined in the combination treatment group, and immunoblotting as well as immunohistochemistry confirmed the upregulation of p21cip1/waf1. The increase in residual γH2AX foci leads to the blockage of cell cycle transition and subsequently to cell death, which could be observed in the upregulation of p21cip1/waf1 expression and an elevated number of cleaved caspase-3 positive cells. Overall, a complex interplay between DNA damage repair and programmed cell death accounts for the potential benefit of the combination therapy using 90Y-Cetuximab and external radiotherapy.

Stereotactic Body Radiation Therapy (SBRT) for prostate cancer: Preliminary results of toxicity

To the Editor, Prostate cancer is the second most common cancer in men in Morocco after lung cancer. External radiotherapy (RTE) is a curative therapeutic option for localized prostate cancer, However the conventional RTE remains a long treatment (7- 8 weeks, 5 days a week) which is demanding for patients and make difficult to manage the waiting lists. The development of imaging and irradiation techniques over the last decades has allowed a high precision in the delivery of the dose to the target organ and a better protection of the organs at risk (OAR), which has encouraged the hypo fractionated irradiation of localized prostate cancer, especially after the results of radiobiology studies that suggested a low report a/b for the prostate.

Rhabdomyosarcoma of the prostate in children: A Case Report

Context: The therapeutic transition from mutilating surgery to external radiotherapy followed by brachytherapy is increasingly effective in the treatment of rhabdomyosarcoma. Case presentation: 13-year-old child with no medical and surgical history, received for complete urine retention. Imaging examinations revealed a prostatic mass of 6 cm. The anatomopathological examination reveals an embryonic rhabdomyosarcoma. There was no recurrence after 3 years of follow-up after a multimodal treatment combining chemotherapy, external radiotherapy and high dose interstitial brachytherapy. Conclusion: Vesicoprostatic rhabdomyosarcomas in children are rare. The therapeutic strategy has evolved over the years owing to the technological advances in external radiotherapy and brachytherapy.